Relative bioavailability of ofloxacin tablets in comparison to oral solution

References

• Auckenthaler R., Michèa-Hamzehpour M., Pichère J. C. In vitro activity of newer quinolones against aerobic bacteria. J. Antimicrob. Chemother. 1986; 17: Suppl. B, 29–391. Auckenthaler R., Michèa-Hamzehpour M., Pichère J. C. In vitro activity of newer quinolones against aerobic bacteria. J. Antimicrob. Chemother. 1986; 17: Suppl. B, 29–39
   PubMed Web of Science ®Google Scholar
• Blomer R., Bruch K., Zahlten R. N. Zusammengefaste Ergebnisse der klinischen Phase-II und -III Studien mit Ofloxacin (HOE 280) in Europa. Infection 1986; 14: Suppl. 1, 102–2072. Blomer R., Bruch K., Zahlten R. N. Zusammengefaste Ergebnisse der klinischen Phase-II und -III Studien mit Ofloxacin (HOE 280) in Europa. Infection 1986; 14: Suppl. 1, 102–207
   Google Scholar
• Couraud L., Bourtillan J. B., Saux M. C., Bryskier A., Vincent de Laurier M. Diffusion von Ofloxacin in menschliches Lungengewebe. Infection 1986; 14: Suppl. 1, 65–663. Couraud L., Bourtillan J. B., Saux M. C., Bryskier A., Vincent de Laurier M. Diffusion von Ofloxacin in menschliches Lungengewebe. Infection 1986; 14: Suppl. 1, 65–66
   Google Scholar
• Cullmann W., Stieglitz M., Baars B., Opferkuch W. Comparative evaluation of recently developed quinolone compounds – with a note on the frequency of resistant mutants. Chemotherapy. 1985; 31: 19–284. Cullmann W., Stieglitz M., Baars B., Opferkuch W. Comparative evaluation of recently developed quinolone compounds – with a note on the frequency of resistant mutants. Chemotherapy. 1985; 31: 19–28
   PubMed Web of Science ®Google Scholar
• Dagrosa E., Verho M., Malerczyk V., De Looze S., Toyodera K. Multiple-dose pharmacokinetics of ofloxacin, a new broad spectrum antimicrobial agent. Clin. Ther. 1986; 8: 632–6455. Dagrosa E., Verho M., Malerczyk V., De Looze S., Toyodera K. Multiple-dose pharmacokinetics of ofloxacin, a new broad spectrum antimicrobial agent. Clin. Ther. 1986; 8: 632–645
   PubMed Web of Science ®Google Scholar
• Davies B. I., Maesen F. P. V., Geraedts W., Baur C. Penetration of ofloxacin from serum to sputum. Drugs. 1987, In press6. Davies B. I., Maesen F. P. V., Geraedts W., Baur C. Penetration of ofloxacin from serum to sputum. Drugs. 1987, In press
   Web of Science ®Google Scholar
• Giamarellou H., Tsagarakis J. Efficacy and tolerance of oral ofloxacin in treating various infections. Drugs. 1987, In press7. Giamarellou H., Tsagarakis J. Efficacy and tolerance of oral ofloxacin in treating various infections. Drugs. 1987, In press
   PubMed Web of Science ®Google Scholar
• Gordts B., Ruhman M., Coignan H., Butzler J. P. Comparative susceptibility study of 401 selected clinical isolates to ofloxacin (HOE 280) and control antimicrobials. Paper read at 24th Int. Sci. Conf., Washington DC, 19848. Gordts B., Ruhman M., Coignan H., Butzler J. P. Comparative susceptibility study of 401 selected clinical isolates to ofloxacin (HOE 280) and control antimicrobials. Paper read at 24th Int. Sci. Conf., Washington DC, 1984
   Google Scholar
• Goto S., Fujimoto T., Tsuji A. In vitro and in vivo antibacterial activity of DL-8280, a new pyridone carboxylic acid derivative. “Ofloxacin, DL-8280; Broad spectrum antibacterial agent. Selected Proceedings from the 13th International Congress of Chemotherapy, Vienna, 1983. Poster Presentations”. Excerpta Medica, Tokyo 1983; 29–349. Goto S., Fujimoto T., Tsuji A. In vitro and in vivo antibacterial activity of DL-8280, a new pyridone carboxylic acid derivative. “Ofloxacin, DL-8280; Broad spectrum antibacterial agent. Selected Proceedings from the 13th International Congress of Chemotherapy, Vienna, 1983. Poster Presentations”. Excerpta Medica, Tokyo 1983; 29–34
   Google Scholar
• Heppleston C., Richmond S., Bailey J. Antichlamydial activity of quinolone carboxylic acids. J. Antimicrob. Chemother. 1985; 15: 645–64710. Heppleston C., Richmond S., Bailey J. Antichlamydial activity of quinolone carboxylic acids. J. Antimicrob. Chemother. 1985; 15: 645–647
   PubMed Web of Science ®Google Scholar
• Ichihara N., Tachizawa H., Tsumura M., Une T., Sato K. Phase I studies on DL-8280. Chemotherapy 1984; 32: Suppl. 1, 118–14911. Ichihara N., Tachizawa H., Tsumura M., Une T., Sato K. Phase I studies on DL-8280. Chemotherapy 1984; 32: Suppl. 1, 118–149
   Google Scholar
• Kagawa K., Sawa K., Takeuchi M., Umemura A., Watanabe K., Ueno K. In vitro activity of DL-8280 against anaerobic bacteria. Chemotherapy (Tokyo) 1984; 32: Suppl. 1, 52–5812. Kagawa K., Sawa K., Takeuchi M., Umemura A., Watanabe K., Ueno K. In vitro activity of DL-8280 against anaerobic bacteria. Chemotherapy (Tokyo) 1984; 32: Suppl. 1, 52–58
   Google Scholar
• Kosakai N., Oguri T. Antibacterial activity of DL-8280 against various bacteria recently isolated from clinical materials. Chemotherapy (Tokyo). 1984; 32: Suppl. 1, 13–2113. Kosakai N., Oguri T. Antibacterial activity of DL-8280 against various bacteria recently isolated from clinical materials. Chemotherapy (Tokyo). 1984; 32: Suppl. 1, 13–21
   Google Scholar
• Kumada T., Neu H. C. (1983) DL-8280, a quinolone antibacterial agent with broad-spectrum activity. In: Ofloxacin, DL-8280; Broad spectrum antibacterial agent. Poster Presentations. Selected Proceedings from the 13th International Congress of Chemotherapy, Vienna, 1983. Excerpta Medica, Tokyo, 1–814. Kumada T., Neu H. C. (1983) DL-8280, a quinolone antibacterial agent with broad-spectrum activity. In: Ofloxacin, DL-8280; Broad spectrum antibacterial agent. Poster Presentations. Selected Proceedings from the 13th International Congress of Chemotherapy, Vienna, 1983. Excerpta Medica, Tokyo, 1–8
   Google Scholar
• Masuda G., Negishi M., Young C., Mizuoka K. (1983) Timed bacteriostatic and bactericidal activities of DL-8280 against E. coli. Klebsiella sp. and S. aureus. “Ofloxacin, DL-8280; Broad spectrum antibacterial agent. Selected Proceedings from the 13th International Congress of Chemotherapy Poster Presentations”, Vienna, 1983. Excerpta Medica, Tokyo, 19–2315. Masuda G., Negishi M., Young C., Mizuoka K. (1983) Timed bacteriostatic and bactericidal activities of DL-8280 against E. coli. Klebsiella sp. and S. aureus. “Ofloxacin, DL-8280; Broad spectrum antibacterial agent. Selected Proceedings from the 13th International Congress of Chemotherapy Poster Presentations”, Vienna, 1983. Excerpta Medica, Tokyo, 19–23
   Google Scholar
• Metzler C. M., Elfring G. L., McEwen A. J. A package of computer programs for pharmacokinetic modeling. Biometrics 1974; 30: 56216. Metzler C. M., Elfring G. L., McEwen A. J. A package of computer programs for pharmacokinetic modeling. Biometrics 1974; 30: 562
   Web of Science ®Google Scholar
• Meyer H. Ofloxacin in cystic fibrosis. Drugs. 1987, In press17. Meyer H. Ofloxacin in cystic fibrosis. Drugs. 1987, In press
   PubMed Web of Science ®Google Scholar
• Naber K. G., Adam D., Wittenberger R., Bartosik-Wich B. In vitro-Aktivität. Serum-, Urin- und Prostata-adenom-Gewebekonzentrationen von Ofloxacin bei urologischen Patienten und komplizierten Harnwegsinfektionen. Infection 1986; 14: Suppl. 1, 60–6418. Naber K. G., Adam D., Wittenberger R., Bartosik-Wich B. In vitro-Aktivität. Serum-, Urin- und Prostata-adenom-Gewebekonzentrationen von Ofloxacin bei urologischen Patienten und komplizierten Harnwegsinfektionen. Infection 1986; 14: Suppl. 1, 60–64
   Google Scholar
• Nishino T., Tanaka M., Kawabata S., Yaba C., Yamanaka K., Tanino T. Bacteriological evaluation of DL-8280, a new synthetic antimicrobial agent. Chemotherapy (Tokyo) 1984; 32: Suppl. 1, 62–8319. Nishino T., Tanaka M., Kawabata S., Yaba C., Yamanaka K., Tanino T. Bacteriological evaluation of DL-8280, a new synthetic antimicrobial agent. Chemotherapy (Tokyo) 1984; 32: Suppl. 1, 62–83
   Google Scholar
• Osada Y., Ogawa H. Antimycoplasmal activity of ofloxacin (DL-8280). Antimicrob. Agents Chemother. 1983; 23: 509–51120. Osada Y., Ogawa H. Antimycoplasmal activity of ofloxacin (DL-8280). Antimicrob. Agents Chemother. 1983; 23: 509–511
   PubMed Web of Science ®Google Scholar
• Rubinstein E., Mark Z., Keren G., Alkan M., Berger S., Bogokowski B. Comparative activity of ofloxacin with reference to bacterial strains isolated in in-patients and out-patients. Infection 1986; 14: Suppl. 1, 20–2521. Rubinstein E., Mark Z., Keren G., Alkan M., Berger S., Bogokowski B. Comparative activity of ofloxacin with reference to bacterial strains isolated in in-patients and out-patients. Infection 1986; 14: Suppl. 1, 20–25
   Google Scholar
• Saito A., Savatari K., Fukada Y., Nagasawa M., Koga H., Tomonaga A., Nakazato H., Fujita K., Shigeno Y., Suzuyama Y. Susceptibility of legionella pneumophila to ofloxacin in vitro and in experimental legionella pneumonia in guinea-pigs. Antimicrob. Agents Chemother. 1985; 28: 15–2022. Saito A., Savatari K., Fukada Y., Nagasawa M., Koga H., Tomonaga A., Nakazato H., Fujita K., Shigeno Y., Suzuyama Y. Susceptibility of legionella pneumophila to ofloxacin in vitro and in experimental legionella pneumonia in guinea-pigs. Antimicrob. Agents Chemother. 1985; 28: 15–20
   PubMed Web of Science ®Google Scholar
• Sato K., Hirai K., Inoue M., Mitsuhashi S. Antibacterial activity of ofloxacin (DL-8280) and its mode of bactericidal action. Paper read at 24th Int. Sci. Conf., Washington DC, 198423. Sato K., Hirai K., Inoue M., Mitsuhashi S. Antibacterial activity of ofloxacin (DL-8280) and its mode of bactericidal action. Paper read at 24th Int. Sci. Conf., Washington DC, 1984
   Google Scholar
• Sato K., Inoue M., Mitsuhashi S. In vitro and in vivo antibacterial activity of DL-8280. Chemotherapy (Tokyo) 1984; 32: Suppl. 1, 1–1224. Sato K., Inoue M., Mitsuhashi S. In vitro and in vivo antibacterial activity of DL-8280. Chemotherapy (Tokyo) 1984; 32: Suppl. 1, 1–12
   Google Scholar
• Scribner R., Weber A., Marrks M. I. In vitro activity of ofloxacin against bacterial isolated from pediatric patients. Proceedings of 24th ICAAC, Washington DC, 1984. Excerpta Medica, Tokyo 1985; 14–2125. Scribner R., Weber A., Marrks M. I. In vitro activity of ofloxacin against bacterial isolated from pediatric patients. Proceedings of 24th ICAAC, Washington DC, 1984. Excerpta Medica, Tokyo 1985; 14–21
   Google Scholar
• Seibert G., Limbert M., Klesel N. Comparison of the antibacterial in vitro and in vivo activity of ofloxacin (HOE 280, DL 8280) and nalidixic acid analogues. Eur. J. Clin. Microbiol. 1983; 2: 548–55326. Seibert G., Limbert M., Klesel N. Comparison of the antibacterial in vitro and in vivo activity of ofloxacin (HOE 280, DL 8280) and nalidixic acid analogues. Eur. J. Clin. Microbiol. 1983; 2: 548–553
   PubMedGoogle Scholar
• Smith J. T. Wirkmechanismus der Chinolone. Infection 1986; 14: Suppl. 1, 3–1527. Smith J. T. Wirkmechanismus der Chinolone. Infection 1986; 14: Suppl. 1, 3–15
   Google Scholar
• Sturm W., Stahler G., Adam D. Bestimmung der Konzentration von Ofloxacin in Rinden- und Markgewebe menschlicher Nieren. FAC. 1987, In press28. Sturm W., Stahler G., Adam D. Bestimmung der Konzentration von Ofloxacin in Rinden- und Markgewebe menschlicher Nieren. FAC. 1987, In press
   Google Scholar
• Suzuyama Y., Shigeno Y., Yamaguchi K., Saito A., Hara K. (1983) Laboratory and clinical studies on DL-8280 in respiratory tract infections. In: Ofloxacin, DL-8280; Broad spectrum antibacterial agent. Selected Proceedings from the 13th International Congress of Chemotherapy Poster Presentations, Vienna, 1983. Excerpta Medica, Tokyo, 110–11429. Suzuyama Y., Shigeno Y., Yamaguchi K., Saito A., Hara K. (1983) Laboratory and clinical studies on DL-8280 in respiratory tract infections. In: Ofloxacin, DL-8280; Broad spectrum antibacterial agent. Selected Proceedings from the 13th International Congress of Chemotherapy Poster Presentations, Vienna, 1983. Excerpta Medica, Tokyo, 110–114
   Google Scholar
• Tanimura H., Kobayashi N., Inamoto T., Kato H., Saito T. Chemotherapy of biliary tract infections (XXI)-excretion into bile, tissue levels of gallbladder and clinical effects of DL-8280 for biliary tract infections. Chemotherapy (Tokyo) 1984; 32: Suppl. 1, 865–88430. Tanimura H., Kobayashi N., Inamoto T., Kato H., Saito T. Chemotherapy of biliary tract infections (XXI)-excretion into bile, tissue levels of gallbladder and clinical effects of DL-8280 for biliary tract infections. Chemotherapy (Tokyo) 1984; 32: Suppl. 1, 865–884
   Google Scholar
• Verho M., Malerczyk V., Dagrosa E., Korn A. Dose linearity and other pharmacokinetics of ofloxacin, a new broad spectrum antimicrobial agent. Pharmatherapeutica 1985; 4: 376–38231. Verho M., Malerczyk V., Dagrosa E., Korn A. Dose linearity and other pharmacokinetics of ofloxacin, a new broad spectrum antimicrobial agent. Pharmatherapeutica 1985; 4: 376–382
   PubMedGoogle Scholar
• Verho M., Malerczyk V., Dagrosa E., Korn A. The effect of food on pharmacokinetics of ofloxacin. Curr. Med. Res. Opin. 1986; 10: 166–17132. Verho M., Malerczyk V., Dagrosa E., Korn A. The effect of food on pharmacokinetics of ofloxacin. Curr. Med. Res. Opin. 1986; 10: 166–171
   PubMed Web of Science ®Google Scholar
• Wagner J. G. Fundamentals of Clinical Pharmacokinetics. Drug Intelligence Publications, Hamilton, Ill. 197933. Wagner J. G. Fundamentals of Clinical Pharmacokinetics. Drug Intelligence Publications, HamiltonIll. 1979
   Google Scholar
• Wittmann D. H., Kotthaus E. Further methodological improvement in antibiotic bone concentration measurements: penetration of ofloxacin into bone and cartilage. Infection 1986; 14: Suppl. 4, 270–27334. Wittmann D. H., Kotthaus E. Further methodological improvement in antibiotic bone concentration measurements: penetration of ofloxacin into bone and cartilage. Infection 1986; 14: Suppl. 4, 270–273
   Google Scholar